Founded in 2015, New Horizon Health Limited (the “Company”) is the pioneer and leader in China’s colorectal cancer screening market, focusing on high-incidence cancer and home-based early cancer screening. The Company has a mission to advance the innovation and accelerate the adoption of cancer screening technologies in China. The Company has two commercialized medical tests for colorectal cancer screening (ColoClear® and Pupu Tube®) approved by the National Medical Products Administration of China (“NMPA”). ColoClear is the first and only cancer screening test in China approved by NMPA. In addition, the Company has two late-stage pipeline candidates for gastric and cervical cancer screening respectively. The Company holds global rights to all its marketed and pipeline products.

 

New Horizon Health has invested by highly reputable VC/PE firms, including VMS Group, Qiming Venture, Legend Capital, Softbank China and more. New Horizon Health (SEHK:6606) officially listed on the Main Board of Hong Kong Stock Exchange (HKEx) on 18 Feb 2021. This is the first listed Chinese cancer early screening company.